Journal of immunotherapy : official journal of the Society for Biological Therapy
about
Improving responses in hepatomas with circadian-patterned hepatic artery infusions of recombinant interleukin-2Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.Alterations of platelet function induced by interleukin-2.Cytokines and Immune Response in the Tumor Microenvironment.Induction of cytokine production from human monocytes stimulated with alginate.Antisense inhibition of gene expression: a tool for studying the role of NMYC in the growth and differentiation of neuroectoderm-derived cells.Growth factors, receptor kinases, and protein tyrosine phosphatases in normal and malignant melanocytes.Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome.Interactions of cytokines with the hypothalamus-pituitary axis.Immunobiology of primary murine melanomas.Tumor-specific antigens of mouse tumors.The use of congenitally immunodeficient mice to study human tumor metastases and immunotherapy.Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes.Reversible cardiomyopathy after high-dose interleukin-2 therapy.Lack of antihypertensive effect of interleukin-2 administration in humans.Sequential Administration of Interferon-gamma, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial.Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells.Phase I study of recombinant human interleukin-2 for pediatric malignancies: feasibility of outpatient therapy. A Pediatric Oncology Group Study.Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer.A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer.Comparative in vitro studies of the potentiation of tumor necrosis factor (TNF)-alpha, TNF-beta, and TNF-SAM2 cytotoxicity by hyperthermia.A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience.Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study.Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma.Expression of the Chemokines IP-10 and Mig in IL-10 Transduced Tumors.Generation of Cytotoxic T Lymphocytes Specific for Human Cytomegalovirus Using Dendritic Cells In Vitro.Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer.Cytokine and natural killing regulation of growth of a hairy cell leukemia-like cell line: the role of interferon-alpha and interleukin-2.Interleukin-2 with ex vivo activated killer cells: therapy of advanced non-small-cell lung cancer.Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells.Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration.Damage to mitochondrial respiration chain is related to phospholipase A2 activation caused by tumor necrosis factor.Gene transfer in human lymphocytes using a vector based on adeno-associated virus.In vitro and in vivo effects of recombinant human interleukin-2 in naive miniature swine.Growth inhibition of human colorectal carcinoma cell lines by tumor necrosis factor-alpha correlates with reduced activity of pp60c-src.
P1433
Q28243013-FD2F925E-53D4-4BB1-B906-24FCED187F80Q33189000-92A1B09C-1399-4792-A531-72DEA5CE95E9Q33376833-52D8C418-8D3D-41C3-8057-5F96CBB95F96Q33376834-5D361B5F-AB73-4F77-8B6F-837BFC86E0B1Q34422285-CE4E4714-7A63-4F3F-AEAD-8028E7C1C680Q34968426-611C1E22-BCEA-433E-A8C8-9D54F40C70B0Q35236058-D51A9926-40ED-4114-BBB5-CE7BCDD2381AQ35535479-62646342-C15E-4AA9-A82B-4C71456B31BAQ35535484-72D28977-3B82-491B-A9B9-2D7B8C57A177Q35535489-C9CC0485-A64E-4729-968E-4899A1773F1FQ35535493-36C8E047-F306-491F-A932-55FB397D40B9Q35535496-E70AF7CC-F356-4715-B817-138772EA2126Q35535501-71D93228-9E64-47DC-B206-2B32AE5F9638Q35535509-3FCA2718-9604-4202-AA6F-A547A2BBE284Q35778775-65F149F8-FE43-45D9-A46F-DC01594C68C9Q36905341-FCDBA49A-8573-44E6-8C0A-FD8AE133FCC7Q40601779-34B844C6-B834-4149-98AB-FFD0824A8B02Q40697584-CC812514-E8D1-4700-B5BF-68A30795276FQ40730747-144C1209-39B9-43CF-89DE-FCE4C37F7443Q40734236-E797E202-7B52-4CBD-AFD0-349692B2A9F9Q40735475-6FFDAC19-EA2F-4DF3-BA16-4EDB12B0ADBEQ40737666-AB7C6C52-1CC1-4BB8-A10A-0A35221BE4A0Q40737673-50F31B85-6FE4-4433-8885-96C180F8A0CEQ40738550-FAE023E0-751A-4499-83B5-D01880B4FBB0Q40742229-C89FB42C-4644-4CDE-A287-007847A75DA7Q40748161-7023AABA-4F7F-4466-9540-F99F273595F2Q40752000-A94D3268-FC24-493A-B358-2EFF87497911Q40752396-87245030-CB26-4CBA-9E3B-007BEC42535AQ40793092-C0095E26-5761-4AED-A61F-A6B1FA21C7BEQ40800638-77B02D95-BD14-4B2A-ADB3-32E9140C8650Q40800644-5FF61F6E-E19E-4DB4-BC78-B3DCF444407DQ41142336-11B47BDD-CF80-48C2-AD48-1D98E7CBA23BQ41142615-F76FC96D-6C4A-41C4-B711-791B9B4F0EF5Q41595020-4F877365-679B-4F18-AC13-07DBBE7E3D7AQ41614732-056FF4DC-4B9C-4B57-A991-B770F6F56D55Q41614738-89222805-FFB5-48E4-955C-723947503D5EQ41617551-B9FC0338-73A6-46E4-A7CB-E3F048B790C5Q41627514-396B34AD-49BB-431D-B17F-71D327934155Q41632196-451B4FF4-7F91-45AD-8A43-6D2DDA53C493Q41632404-23E64EF0-148E-474E-86D5-4B81BA3140EC
P1433
Journal of immunotherapy : official journal of the Society for Biological Therapy
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Lippincott Williams & Wilkins
@nl
wissenschaftliche Fachzeitschrift
@de
name
Journal of immunotherapy : official journal of the Society for Biological Therapy
@ast
Journal of immunotherapy : official journal of the Society for Biological Therapy
@en
Journal of immunotherapy : official journal of the Society for Biological Therapy
@es
Journal of immunotherapy : official journal of the Society for Biological Therapy
@it
Journal of immunotherapy : official journal of the Society for Biological Therapy
@nl
type
label
Journal of immunotherapy : official journal of the Society for Biological Therapy
@ast
Journal of immunotherapy : official journal of the Society for Biological Therapy
@en
Journal of immunotherapy : official journal of the Society for Biological Therapy
@es
Journal of immunotherapy : official journal of the Society for Biological Therapy
@it
Journal of immunotherapy : official journal of the Society for Biological Therapy
@nl
altLabel
J Immunother (1991)
@en
J. Immunother.
@en
prefLabel
Journal of immunotherapy : official journal of the Society for Biological Therapy
@ast
Journal of immunotherapy : official journal of the Society for Biological Therapy
@en
Journal of immunotherapy : official journal of the Society for Biological Therapy
@es
Journal of immunotherapy : official journal of the Society for Biological Therapy
@it
Journal of immunotherapy : official journal of the Society for Biological Therapy
@nl
P1055
P1156
P1476
Journal of immunotherapy : official journal of the Society for Biological Therapy
@en